1. Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res Part C Embryo Today Rev. 2015;105(2):140–56. https://doi.org/10.1002/bdrc.21096.
2. Information on the Member States requirement for the nomination of a pharmacovigilane (PhV) contact person at national level. London, United Kingdom: European Medicines Agency; 2017. https://www.ema.europa.eu/en/documents/other/information-member-states-requirement-nomination-pharmacovigilance-phv-contact-person-national-level_en.pdf. Accessed 4 June 2020.
3. Guidelines for qualified person for pharmacovigilance. Ghana, Accra: Food and Drugs Authority; 2013. https://www.rrfa.co.za/wp-content/uploads/2017/01/Ghana-Guidelines-for-Qualified-Person-for-Pharmacovigilance-1802.pdf. Accessed 4 June 2020.
4. Guidelines for the establishment of the qualified persons for pharmacovigilance. Nairobi, Kenya: Pharmacy and Poisons Board Kenya; 2018. https://pharmacyboardkenya.org/downloads. Accessed 4 June 2020.
5. Frehywot S, Vovides Y, Talib Z, Mikhail N, Ross H, Wohltjen H, et al. E-learning in medical education in resource constrained low- and middle-income countries. Hum Resour Health. 2013;11(1):4. https://doi.org/10.1186/1478-4491-11-4.